CAS No.
755037-03-7(Unlabeled)
Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-(methyl-13C-d3)-2-pyridinecarboxamide
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for accurate information
Useful research chemical for a range of applications
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Regorafenib-13C,d3 usage and description
Regorafenib 13CD3 is a modified version of Regorafenib, an oral medication used to treat certain types of cancer. The drug works by blocking several enzymes that promote the growth of cancer cells, ultimately slowing or stopping their progression.
Regorafenib 13CD3 is labeled as a “deuterated” version of the original medication, meaning that it has been chemically modified to replace some of the hydrogen atoms with deuterium atoms. This alteration can have several benefits, including increased stability and an extended half-life, which can lead to a longer-lasting and more effective treatment.
The chemical formula for Regorafenib 13CD3 is C21H11ClF4N4O3D3, and it has a molecular weight of 482.90 g/mol. It is typically administered orally in tablet form and is rapidly absorbed into the bloodstream, with peak plasma concentrations occurring within 3-4 hours of ingestion.
While Regorafenib 13CD3 has been shown to be effective in treating certain types of cancer, it can also cause side effects such as fatigue, diarrhea, and hypertension. Patients considering treatment with this medication should discuss the potential benefits and risks with their healthcare provider, and should be monitored closely for any adverse effects. Overall, Regorafenib 13CD3 is a powerful tool in the fight against cancer, and its unique chemical structure may offer additional benefits to patients in need of treatment.
